Molly M. Baldwin

Molly M. Baldwin

Auto-generated profile, based on publicly available information

Molly M. Baldwin

NIHR Leicester Biomedical Research Centre, Leicester, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in European Respiratory Journal
Verified
Journal Article
Open access
EDEnya Daynes
Enya Daynes
RERachael A. Evans
Rachael A. Evans
NGNeil J. Greening
Neil J. Greening
NBNicolette C. Bishop
Nicolette C. Bishop
TYThomas Yates
Thomas Yates
SSSally J. Singh
Sally J. Singh
Objective: Post-COVID syndrome involves prolonged symptoms with multisystem and functional impairment lasting ≥12 weeks after acute coronavirus disease 2019 (COVID-19). We aimed to determine the efficacy of exercise-based rehabilitation interventions, either face-to-face or remote, compared to usual care in individuals experiencing post-COVID syndrome following a hospitalisation with acute COVID-19.Design: This single-blind randomised controlled trial compared two exercise-based rehabilitation interventions (face-to-face or remote) to usual care in participants with post-COVID syndrome following a hospitalisation. The interventions were either a face-to-face or remote 8-week programme of individually prescribed exercise and education. The primary outcome was the change in Incremental Shuttle Walking Test (ISWT) following 8 weeks of intervention (either face-to-face or remote) compared to usual care. Other secondary outcomes were measured including health-related quality of life (HRQoL), and exploratory outcomes included lymphocyte immunotyping.Results: 181 participants (55% male, mean±sdage 59±12 years, length of hospital stay 12±19 days) were randomised. There was an improvement in the ISWT distance following face-to-face rehabilitation (mean 52 m, 95% CI 19–85 m; p=0.002) and remote rehabilitation (mean 34 m, 95% CI 1–66 m; p=0.047) compared to usual care alone. There were no differences between groups for HRQoL self-reported symptoms. Analysis of immune markers revealed significant increases in naïve and memory CD8+T-cells following face-to-face rehabilitationversususual care alone (p<0.001, n=31).Conclusion: Exercise-based rehabilitation improved short-term exercise capacity in post-COVID syndrome following an acute hospitalisation and showed potential for beneficial immunomodulatory effects.

9 May 2024 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
EDEnya Daynes
Enya Daynes
MBMolly M. Baldwin
Molly M. Baldwin
MAMatthew Annals
Matthew Annals
NGNikki Gardiner
Nikki Gardiner
ECEmma Chaplin
Emma Chaplin
SSSally J. Singh
Sally J. Singh
Background: There is evidence to support COVID-19 rehabilitation programmes improving persistent COVID-19 symptoms; however, there is concern that therapies that include an exercise component may increase fatigue and post-exertional symptom exacerbation (PESE). The objectives of the present study were to determine the effect of a 6-week COVID-19 rehabilitation programme on fatigue and PESE in individuals with ongoing COVID-19 symptoms.Methods: After a routine medical assessment, individuals with persistent COVID-19 symptoms were enrolled on a 6-week COVID-19 specific rehabilitation programme. The programme included symptom-titrated exercise, education and self-management advice. Fatigue was assessed pre- and post-programme using the Functional Assessment Chronic Illness Therapy Fatigue questionnaire (FACIT). Exercise capacity (Incremental and Endurance Shuttle Walking Test (ISWT and ESWT)) and PESE (DePaul Symptom Questionnaire (DSQ)) were also assessed pre- and post-programme. Composite scores were calculated for the frequency and severity domains of the DSQ.Results: 148 patients (median (IQR) age 59 (49–72) years, 82 (55%) female, 81 (54%) hospitalised) completed the COVID-19 rehabilitation programme. FACIT score was reduced pre- to post-programme by a mean (CI) change of −5 (−7– −4); p<0.01. Exercise capacity increased by 82 (65–99) m for the ISWT and 398 (333–462) s for the ESWT (n=148). PESE was assessed in 44 patients. The DSQ frequency and severity composite score improved by 20 (13–28) and 19 (13–26) points, respectively (p<0.01, n=44).Conclusion: These data demonstrate the potential benefits of a COVID-19 rehabilitation programme in improving fatigue, exercise capacity and symptom exacerbation in those with persistent COVID-19 symptoms.

22 August 2024 in Chest
Verified
Journal Article
Open access
THTheresa C. Harvey-Dunstan
Theresa C. Harvey-Dunstan
MBMolly M. Baldwin
Molly M. Baldwin
RTRuth Tal-Singer
Ruth Tal-Singer
MAMatthew Allinder
Matthew Allinder
MPMichael I. Polkey
Michael I. Polkey
SSSally J. Singh
Sally J. Singh
COPD is characterized by reduced exercise tolerance, and improving physical performance is an important therapeutic goal. A variety of exercise tests are commonly used to assess exercise tolerance, including laboratory and field-based tests. The responsiveness of these various tests to common COPD interventions is yet to be compared, but the results may inform test selection in clinical and research settings. What exercise test possesses the greatest sensitivity to change from before to after intervention in patients with COPD? One hundred fifty-four patients with symptomatic COPD were recruited and randomized (2:1:1) to 6 weeks of long-acting muscarinic antagonist, pulmonary rehabilitation (PR), or usual care. Before and after intervention, participants performed an incremental cycle exercise test and constant work rate cycle test (CWRCT), incremental shuttle walk test and endurance shuttle walk test (ESWT), 6-min walk test, and 4-m gait speed test. One hundred three participants (mean ± SD age, 67 ± 8 years; 75 male participants [73%]; FEV1, 50.6 ± 16.8% predicted) completed the study. Significant improvements in the incremental cycle exercise test, CWRCT, incremental cycle exercise test, ESWT, and 6-min walk test results were observed after PR (P < .05), with the greatest improvements seen in the constant work rate protocols (percentages change: CWRCT, 42%; ESWT, 41%). The ESWT and CWRCT seemed to be the most responsive exercise test protocols to long-acting muscarinic antagonist and PR therapy. The magnitude of change was much greater after a program of rehabilitation compared with bronchodilator therapy. International Standard Randomised Controlled Trial Number (ISRCTN): No. 64759523; URL: https://www.isrctn.com/ISRCTN64759523

11 March 2024 in Medicine & Science in Sports & Exercise
Verified
Journal Article
Open access
MBMolly M. Baldwin
Molly M. Baldwin
MCMatt R. Chadwick
Matt R. Chadwick
ABAlan P. Benson
Alan P. Benson
HRHarry Rossiter
Harry Rossiter
CFCarrie Ferguson
Carrie Ferguson
Introduction: Traditional neuromuscular fatigue assessments are not task-specific and are unable to characterize neuromuscular performance decline during dynamic whole-body exercise. This study used interleaved maximal isokinetic cycling efforts to characterize the dynamics of the decline in neuromuscular performance during ramp-incremental (RI) cycle ergometry exercise to intolerance. Methods: Eleven young healthy participants (10 male/1 female) performed two RI cycle ergometry exercise tests to intolerance: 1) RI exercise with peak isokinetic power (Piso) at 80 rpm measured at baseline and immediately at intolerance from a maximal ~6 s effort, and 2) RI exercise where additional Piso measurements were interleaved every 90 s to characterize the decline in neuromuscular performance during the RI test. Muscle excitation was measured using EMG during all Piso assessments, and pulmonary gas exchange was measured throughout. Results: Baseline Piso was 832 ± 140 W and RI exercise reduced Piso to 349 ± 96 W at intolerance ( P = 0.001), which was not different from flywheel power at intolerance (303 ± 96 W; P = 0.292). There was no reduction in Piso between baseline cycling and gas exchange threshold (GET; baseline Piso vs mean Piso below GET: 828 ± 146 vs 815 ± 149 W; P = 1.00). Piso fell progressively above GET until intolerance (Piso every 90 s above GET: 759 ± 139, 684 ± 141, 535 ± 144, 374 ± 117 W; each P < 0.05 vs baseline and mean Piso below GET). Peak muscle excitation (EMG) was also reduced only above GET (73% ± 14% of baseline, at intolerance; P < 0.05). However, the reduction in peak Piso preceded the reduction in peak muscle excitation. Conclusions: The dynamics of the decline in neuromuscular performance (reduction in Piso and EMG) during RI exercise are consistent with known intensity-dependent metabolic and traditional pre–post neuromuscular fatigue responses to discrete bouts of constant-power exercise.

20 January 2023 in JMIR Formative Research
Verified
Journal Article
Open access
MBMolly M Baldwin
Molly M Baldwin
EDEnya Daynes
Enya Daynes
ECEmma Chaplin
Emma Chaplin
AGAmye Goddard
Amye Goddard
PLPhoebe H I Lloyd-Evans
Phoebe H I Lloyd-Evans
SSSally J Singh
Sally J Singh
Background: At the start of the COVID-19 pandemic, unprecedented pressure was placed on health care services globally. An opportunity to alleviate this pressure was to introduce a digital health platform that provided COVID-19–related advice and helped individuals understand and manage their COVID-19 symptoms. Therefore, in July 2020, the Your COVID Recovery website was launched by the National Health Service of England with the aim of creating a practical tool that provides advice and support to individuals recovering from COVID-19. The website includes information on many of the key COVID-19 symptoms. To date, public use of the Your COVID Recovery website and user behavior remain unknown. However, this information is likely to afford insight into the impact of the website and most commonly experienced COVID-19 symptoms. Objective: This study aimed to evaluate public use of the Your COVID Recovery website, a digital health platform that provides support to individuals recovering from COVID-19, and determine user behavior during its first year of operation. Methods: Google Analytics software that was integrated into the Your COVID Recovery website was used to assess website use and user behavior between July 31, 2020, and July 31, 2021. Variables that were tracked included the number of users, user country of residence, traffic source, number of page views, number of session views, and mean session duration. User data were compared to COVID-19 case data downloaded from the UK government’s website. Results: During the study period, 2,062,394 users accessed the Your COVID Recovery website. The majority of users were located in the United Kingdom (1,265,061/2,062,394, 61.30%) and accessed the website via a search engine (1,443,057/2,062,394, 69.97%). The number of daily website users (n=15,298) peaked on January 18, 2021, during the second wave of COVID-19 in the United Kingdom. The most frequently visited pages after the home page were for the following COVID-19 symptoms: Cough (n=550,190, 12.17%), Fatigue (n=432,421, 9.56%), Musculoskeletal pain (n=406,859, 9.00%), Taste and smell (n=270,599, 5.98%), and Breathlessness (n=203,136, 4.49%). The average session duration was 1 minute 13 seconds. Conclusions: A large cohort of individuals actively sought help with their COVID-19 recovery from the website, championing the potential of this tool to target an unmet health care need. User behavior demonstrated that individuals were primarily seeking advice on how to relieve and manage COVID-19 symptoms, especially symptoms of cough, fatigue, and musculoskeletal pain. COVID-19 rehabilitation programs should use the results of this study to ensure that the program content meets the needs of the post–COVID-19 population.

26 June 2025 in ERJ Open Research
Verified
Journal Article
Open access
MBMolly M. Baldwin
Molly M. Baldwin
EDEnya Daynes
Enya Daynes
UKUrvee Karsanji
Urvee Karsanji
HMHamish J.C. McAuley
Hamish J.C. McAuley
NBNicolette C. Bishop
Nicolette C. Bishop
SSSally J. Singh
Sally J. Singh
Background: The incremental shuttle walk test (ISWT) may be a valuable tool for measuring exercise tolerance in patients after a hospital admission with COVID-19. However, the safety, physiological response and repeatability of the ISWT are unknown in this cohort. The present study aimed to explore the properties of this test using the Post-Hospital COVID-19 (PHOSP-COVID) study. Methods: Participants performed two ISWTs, with a 30-min rest between tests, at 5 and 12 months post-hospital discharge for COVID-19. Heart rate and fingertip peripheral oxygen saturation were recorded pre- and post-test. Reasons for test termination were noted. Results: 1593 individuals (median (interquartile range) age 58 (50–66) years and body mass index 31.2 (27.6–35.8) kg·m − 2 ; 967 (60.7%) males) performed an ISWT; two tests were performed by 1034 and 390 participants at the 5- and 12-month visit, respectively. At 5 months post-discharge, six patients (0.4%) had an adverse event and the most common reason contributing to test termination was breathlessness (826 (54.2%) participants). 336/1470 (22.9%) participants experienced exertional desaturation. Distance walked was greater in the second ISWT compared to the first ISWT at 5 and 12 months post-discharge (mean± sd difference: 5 months: 19±94 m; 12 months: 11±80 m; p<0.05), with an intraclass correlation coefficient estimate of 0.96 (95% CI 0.95–0.97) at 5 months and 0.97 (95% CI 0.96–0.97) at 12 months. Conclusions: The ISWT appeared to be safe in this large cohort, supporting use of this field walking test for this population in clinical and research settings. A familiarisation test is recommended, with further study needed to determine the number of familiarisation tests required to achieve acceptable within-day repeatability.